Events and Webinars

IMPORTANT SAFETY INFORMATION

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
Show Past Events Show Future Events
Filter by Date

      • From
      • To
Filter by Date

      • From
      • To

Events and Webinars for SHINGRIX

Heather Hensler, PhD View Bio >>
August 22, 2019 12:15PM PST
Webinar
1h
Ellie H. Donaldson, PharmD View Bio >>
September 11, 2019 12:15PM EST
Webinar
1h
Heather Hensler, PhD View Bio >>
September 12, 2019 12:15PM PST
Webinar
1h
Angili Arora, PharmD View Bio >>
September 17, 2019 12:15PM EST
Webinar
1h
Angili Arora, PharmD View Bio >>
September 18, 2019 7:15PM PST
Webinar
1h
Pooja Joshi, MD View Bio >>
September 25, 2019 6:15PM CST
Webinar
1h
Heather Hensler, PhD View Bio >>
September 26, 2019 12:15PM PST
Webinar
1h
< Page 1 >

IMPORTANT SAFETY INFORMATION

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
  • Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
  • SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

 

Trademarks are property of their respective owners.

SGXWCNT190009 April 2019

INDICATION

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).